Safety and toxicity concerns of orally delivered nanoparticles as drug carriers

Expert Opinion on Drug Metabolism and Toxicology

Volumn 11, Issue 3, 2015, Pages 381-393

  Araújo, Francisca ^a,b,c   Shrestha, Neha ^c   Granja, Pedro L ^a,b   Hirvonen, Jouni ^c   Santos, Hélder A ^c   Sarmento, Bruno ^a,d  

^a INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY INSTITUTE OF HEALTH SCIENCES IUCS   (Portugal)

Author keywords

Carbon; Gold; Lipids; Mesoporous silicon; Nanoparticles; Oral; Polymeric; Silica; Toxicity

Indexed keywords

CARBON NANOPARTICLE; DRUG CARRIER; GOLD NANOPARTICLE; LIPID; METAL NANOPARTICLE; METAL OXIDE; NANOPARTICLE; POLYMER; SILICA NANOPARTICLE; SILICON DIOXIDE;

BIODEGRADABILITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG TRANSPORT; GASTROINTESTINAL TRACT; PARTICLE SIZE; POLYMERIZATION; REVIEW; SURFACE PROPERTY; ANIMAL; BIOAVAILABILITY; CHEMISTRY; HUMAN; NANOTECHNOLOGY; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PROCEDURES; SOLUBILITY;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NANOTECHNOLOGY; PARTICLE SIZE; PHARMACOKINETICS; SOLUBILITY; SURFACE PROPERTIES;

EID: 84922975886     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2015.992781     Document Type: Review

References (115)

1. Nahar M, Mishra D, Dubey V, et al. Development, characterization, and toxicity evaluation of amphotericin b-loaded gelatin nanoparticles. Nanomedicine 2008;4:252-61
2. Jain AK, Swarnakar NK, Godugu C, et al. The effect of the oral administration of polymeric nanoparticles on the efficacy and toxicity of tamoxifen. Biomaterials 2011;32:503-15
3. Foldvari M, Bagonluri M. Carbon nanotubes as functional excipients for nanomedicines: I. Pharmaceutical properties. Nanomedicine 2008;4:173-82
4. Shahbazi MA, Almeida PV, Makila EM, et al. Augmented cellular trafficking and endosomal escape of porous silicon nanoparticles via zwitterionic bilayer polymer surface engineering. Biomaterials 2014;35:7488-500
5. Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech 2011;12:62-76
6. Plapied L, Duhem N, des Rieux A, et al. Fate of polymeric nanocarriers for oral drug delivery. Curr Opin Colloid Interface Sci 2011;16:228-37
7. Choonara BF, Choonara YE, Kumar P, et al. A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules. Biotechnol Adv 2014;32:1269-82
8. Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev 2012;64:557-70
9. Schenk M, Mueller C. The mucosal immune system at the gastrointestinal barrier. Best Pract Res Clin Gastroenterol 2008;22:391-409
10. Bakhru SH, Furtado S, Morello AP, et al. Oral delivery of proteins by biodegradable nanoparticles. Adv Drug Deliv Rev 2013;65:811-21
11. Yun Y, Cho YW, Park K. Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery. Adv Drug Deliv Rev 2013;65:822-32
12. Araujo F, Shrestha N, Shahbazi MA, et al. The impact of nanoparticles on the mucosal translocation and transport of glp-1 across the intestinal epithelium. Biomaterials 2014;35:9199-207
13. Li X, Guo S, Zhu C, et al. Intestinal mucosa permeability following oral insulin delivery using core shell corona nanolipoparticles. Biomaterials 2013;34:9678-87
14. Khan J, Iiboshi Y, Cui L, et al. Role of intestinal mucus on the uptake of latex beads by peyer's patches and on their transport to mesenteric lymph nodes in rats. JPEN J Parenter Enteral Nutr 1999;23:19-23
15. Albanese CT, Cardona M, Smith SD, et al. Role of intestinal mucus in transepithelial passage of bacteria across the intact ileum in vitro. Surgery 1994;116:76-82
16. Lamprecht A, Schäfer U, Lehr C-M. Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res 2001;18:788-93
17. Pridgen EM, Alexis F, Farokhzad OC. Polymeric nanoparticle technologies for oral drug delivery. Clin Gastroenterol Hepatol 2014;12:1605-10
18. Hochman J, Artursson P. Mechanisms of absorption enhancement and tight junction regulation. J Control Release 1994;29:253-67
19. des Rieux A, Pourcelle V, Cani PD, et al. Targeted nanoparticles with novel non-peptidic ligands for oral delivery. Adv Drug Deliv Rev 2013;65:833-44
20. des Rieux A, Fievez V, Garinot M, et al. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release 2006;116:1-27
21. Chen MC, Sonaje K, Chen KJ, et al. A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Biomaterials 2011;32:9826-38
22. McClements DJ. Edible lipid nanoparticles: digestion, absorption, and potential toxicity. Prog Lipid Res 2013;52:409-23
23. nd edition. Sinauer Associates; Sunderland (MA): 2000
24. Hillaireau H, Couvreur P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci 2009;66:2873-96
25. Rekha MR, Sharma CP. Oral delivery of therapeutic protein/peptide for diabetes-future perspectives. Int J Pharm 2013;440:48-62
26. Florence AT. Nanoparticle uptake by the oral route: fulfilling its potential? Drug Discov Today Technol 2005;2:75-81
27. Kean T, Thanou M. Biodegradation, biodistribution and toxicity of chitosan. Adv Drug Deliv Rev 2010;62:3-11
28. Arora S, Rajwade JM, Paknikar KM. Nanotoxicology and in vitro studies: the need of the hour. Toxicol Appl Pharmacol 2012;258:151-65.
29. Reis CP, Figueiredo IV, Carvalho RA, et al. Toxicological assessment of orally delivered nanoparticulate insulin. Nanotoxicology 2008;2:205-17
30. Fonte P, Araujo F, Reis S, et al. Oral insulin delivery: how far are we? J Diabetes Sci Technol 2013;7:520-31
31. Yeh TH, Hsu LW, Tseng MT, et al. Mechanism and consequence of chitosan-mediated reversible epithelial tight junction opening. Biomaterials 2011;32:6164-73
32. Sonaje K, Chuang EY, Lin KJ, et al. Opening of epithelial tight junctions and enhancement of paracellular permeation by chitosan: microscopic, ultrastructural, and computed-tomographic observations. Mol Pharm 2012;9:1271-9
33. Werle M, Takeuchi H, Bernkop-Schnurch A. Modified chitosans for oral drug delivery. J Pharm Sci 2009;98:1643-56
34. Baldrick P. The safety of chitosan as a pharmaceutical excipient. Regul Toxicol Pharmacol 2010;56:290-9
35. Chiu GN, Wong MY, Ling LU, et al. Lipid-based nanoparticulate systems for the delivery of anti-cancer drug cocktails: implications on pharmacokinetics and drug toxicities. Curr Drug Metab 2009;10:861-74
36. Morishita M, Peppas NA. Is the oral route possible for peptide and protein drug delivery? Drug Discov Today 2006;11:905-10
37. Gan Q, Wang T. Chitosan nanoparticle as protein delivery carrier - systematic examination of fabrication conditions for efficient loading and release. Colloids Surf B Biointerfaces 2007;59:24-34
38. Muzzarelli RA, Greco F, Busilacchi A, et al. Chitosan, hyaluronan and chondroitin sulfate in tissue engineering for cartilage regeneration: a review. Carbohydr Polym 2012;89:723-39
39. Hejazi R, Amiji M. Chitosan-based gastrointestinal delivery systems. J Control Release 2003;89:151-65
40. Chae SY, Jang MK, Nah JW. Influence of molecular weight on oral absorption of water soluble chitosans. J Control Release 2005;102:383-94
41. Zheng F, Shi XW, Yang GF, et al. Chitosan nanoparticle as gene therapy vector via gastrointestinal mucosa administration: results of an in vitro and in vivo study. Life Sci 2007;80:388-96
42. Qin C, Gao J, Wang L, et al. Safety evaluation of short-term exposure to chitooligomers from enzymic preparation. Food Chem Toxicol 2006;44:855-61
43. Nishimura Y, Kim HS, Ikota N, et al. Radioprotective effect of chitosan in sublethally x-ray irradiated mice. J Radiat Res 2003;44:53-8
44. Lee KY, Shibutani M, Takagi H, et al. Subchronic toxicity study of dietary n-acetylglucosamine in f344 rats. Food Chem Toxicol 2004;42:687-95
45. Anderson JW, Nicolosi RJ, Borzelleca JF. Glucosamine effects in humans: A review of effects on glucose metabolism, side effects, safety considerations and efficacy. Food Chem Toxicol 2005;43:187-201
46. Yang YM, Hu W, Wang XD, et al. The controlling biodegradation of chitosan fibers by n-acetylation in vitro and in vivo. J Mater Sci Mater Med 2007;18:2117-21
47. Zhang H, Neau SH. In vitro degradation of chitosan by bacterial enzymes from rat cecal and colonic contents. Biomaterials 2002;23:2761-6
48. Schipper NG, Varum KM, Artursson P. Chitosans as absorption enhancers for poorly absorbable drugs. 1: influence of molecular weight and degree of acetylation on drug transport across human intestinal epithelial (caco-2) cells. Pharm Res 1996;13:1686-92
49. Schipper NG, Varum KM, Stenberg P, et al. Chitosans as absorption enhancers of poorly absorbable drugs. 3: influence of mucus on absorption enhancement. Eur J Pharm Sci 1999;8:335-43
50. Agrawal U, Sharma R, Gupta M, et al. Is nanotechnology a boon for oral drug delivery? Drug Discov Today 2014;19:1530-46
51. Arai K, Kinumaki T, Fujita T. Toxicity of chitosan. Bull Tokai Reg Fish Res Lab 1968;56:89-94
52. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Control Release 2004;100:5-28
53. Gades MD, Stern JS. Chitosan supplementation and fecal fat excretion in men. Obes Res 2003;11:683-8
54. Yin L, Ding J, He C, et al. Drug permeability and mucoadhesion properties of thiolated trimethyl chitosan nanoparticles in oral insulin delivery. Biomaterials 2009;30:5691-700
55. Sonaje K, Lin YH, Juang JH, et al. In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery. Biomaterials 2009;30:2329-39
56. Du X, Zhang J, Zhang Y, et al. Decanoic acid grafted oligochitosan nanoparticles as a carrier for insulin transport in the gastrointestinal tract. Carbohydr Polym 2014;111:433-41
57. Woitiski CB, Sarmento B, Carvalho RA, et al. Facilitated nanoscale delivery of insulin across intestinal membrane models. Int J Pharm 2011;412:123-31
58. Woitiski CB, Neufeld RJ, Soares AF, et al. Evaluation of hepatic glucose metabolism via gluconeogenesis and glycogenolysis after oral administration of insulin nanoparticles. Drug Dev Ind Pharm 2012;38:1441-50
59. Zhang X, Sun M, Zheng A, et al. Preparation and characterization of insulin-loaded bioadhesive plga nanoparticles for oral administration. Eur J Pharm Sci 2012;45:632-8
60. Semete B, Booysen LI, Kalombo L, et al. In vivo uptake and acute immune response to orally administered chitosan and peg coated plga nanoparticles. Toxicol Appl Pharmacol 2010;249:158-65
61. Bhardwaj V, Ankola DD, Gupta SC, et al. Plga nanoparticles stabilized with cationic surfactant: safety studies and application in oral delivery of paclitaxel to treat chemical-induced breast cancer in rat. Pharm Res 2009;26:2495-503
62. Semete B, Booysen L, Lemmer Y, et al. In vivo evaluation of the biodistribution and safety of plga nanoparticles as drug delivery systems. Nanomedicine 2010;6:662-71
63. Svenson S, Tomalia DA. Dendrimers in biomedical applications - reflections on the field. Adv Drug Deliv Rev 2005;57:2106-29
64. Thiagarajan G, Greish K, Ghandehari H. Charge affects the oral toxicity of poly (amidoamine) dendrimers. Eur J Pharm Biopharm 2013;84:330-4
65. Wiwattanapatapee R, Carreno-Gomez B, Malik N, et al. Anionic pamam dendrimers rapidly cross adult rat intestine in vitro: a potential oral delivery system? Pharm Res 2000;17:991-8
66. Kalepun S, Manthina M, Padavala V. Oral lipid-based drug delivery systems - an overview. Acta Pharm Sin B 2013;3:361-72
67. Silva AC, Gonzalez-Mira E, Garcia ML, et al. Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (sln): high pressure homogenization versus ultrasound. Colloids Surf B Biointerfaces 2011;86:158-65
68. Rawat MK, Jain A, Singh S. In vivo and cytotoxicity evaluation of repaglinideloaded binary solid lipid nanoparticles after oral administration to rats. J Pharm Sci 2011;100:2406-17
69. Cho HJ, Park JW, Yoon IS, et al. Surface-modified solid lipid nanoparticles for oral delivery of docetaxel: enhanced intestinal absorption and lymphatic uptake. Int J Nanomedicine 2014;9:495-504
70. Xue M, Jiang ZZ, Wu T, et al. Anti-inflammatory effects and hepatotoxicity of tripterygium-loaded solid lipid nanoparticles on adjuvant-induced arthritis in rats. Phytomedicine 2012;19:998-1006
71. Zhou L, Chen Y, Zhang Z, et al. Preparation of tripterine nanostructured lipid carriers and their absorption in rat intestine. Pharmazie 2012;67:304-10
72. Rogers JA, Anderson KE. The potential of liposomes in oral drug delivery. Crit Rev Ther Drug Carrier Syst 1998;15:421-80
73. Lv LZ, Tong CQ, Lv Q, et al. Enhanced absorption of hydroxysafflor yellow a using a self-double-emulsifying drug delivery system: in vitro and in vivo studies. Int J Nanomedicine 2012;7:4099-107
74. Buyukozturk F, Benneyan JC, Carrier RL. Impact of emulsion-based drug delivery systems on intestinal permeability and drug release kinetics. J Control Release 2010;142:22-30
75. Iijima S. Helical microtubules of graphitic carbon. Nature 1991;354:56-8
76. Beg S, Rizwan M, Sheikh AM, et al. Advancement in carbon nanotubes: basics, biomedical applications and toxicity. J Pharm Pharmacol 2011;63:141-63
77. Heister E, Neves V, Tîlmaciu C, et al. Triple functionalisation of single-walled carbon nanotubes with doxorubicin, a monoclonal antibody, and a fluorescent marker for targeted cancer therapy. Carbon 2009;47:2152-60
78. Ajima K, Yudasaka M, Murakami T, et al. Carbon nanohorns as anticancer drug carriers. Mol Pharm 2005;2:475-80
79. Miyawaki J, Yudasaka M, Azami T, et al. Toxicity of single-walled carbon nanohorns. ACS Nano 2008;2:213-26
80. Pulskamp K, Diabate S, Krug HF. Carbon nanotubes show no sign of acute toxicity but induce intracellular reactive oxygen species in dependence on contaminants. Toxicol Lett 2007;168:58-74
81. Park S, An J, Jung I, et al. Colloidal suspensions of highly reduced graphene oxide in a wide variety of organic solvents. Nano Lett 2009;9:1593-7
82. Rahmanian N, Hamishehkar H, Dolatabadi JE, et al. Nano graphene oxide: a novel carrier for oral delivery of flavonoids. Colloids Surf B Biointerfaces 2014. doi: 10.1016/j.colsurfb.2014.09.036
83. Yang K, Gong H, Shi X, et al. In vivo biodistribution and toxicology of functionalized nano-graphene oxide in mice after oral and intraperitoneal administration. Biomaterials 2013;34:2787-95
84. Santos HA, Peltonen L, Limnell T, et al. Mesoporous materials and nanocrystals for enhancing the dissolution behavior of poorly water-soluble drugs. Curr Pharm Biotechnol 2013;14:926-38
85. Santos HA, Makila E, Airaksinen AJ, et al. Porous silicon nanoparticles for nanomedicine: preparation and biomedical applications. Nanomedicine 2014;9:535-54
86. Ambrogio MW, Thomas CR, Zhao YL, et al. Mechanized silica nanoparticles: a new frontier in theranostic nanomedicine. Acc Chem Res 2011;44:903-13
87. Salonen J, Kaukonen AM, Hirvonen J, et al. Mesoporous silicon in drug delivery applications. J Pharm Sci 2008;97:632-53
88. Jaganathan H, Godin B. Biocompatibility assessment of si-based nano- and micro-particles. Adv Drug Deliv Rev 2012;64:1800-19
89. Qu W, Li Y, Hovgaard L, et al. A silica-based ph-sensitive nanomatrix system improves the oral absorption and efficacy of incretin hormone glucagon-like peptide-1. Int J Nanomedicine 2012;7:4983-94
90. Moulari B, Pertuit D, Pellequer Y, et al. The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis. Biomaterials 2008;29:4554-60
91. van der Zande M, Vandebriel RJ, Groot MJ, et al. Sub-chronic toxicity study in rats orally exposed to nanostructured silica. Part Fibre Toxicol 2014;11:8
92. Hassankhani R, Esmaeillou M, Tehrani AA, et al. In vivo toxicity of orally administrated silicon dioxide nanoparticles in healthy adult mice. Environ Sci Pollut Res Int 2014. [Epub ahead of print]
93. Vallet-Regi M, Rámila A, del Real RP, et al. A new property of mcm-41: drug delivery system. Chem Mater 2001;13:308-11
94. Fu C, Liu T, Li L, et al. The absorption, distribution, excretion and toxicity of mesoporous silica nanoparticles in mice following different exposure routes. Biomaterials 2013;34:2565-75
95. Salonen J, Laitinen L, Kaukonen AM, et al. Mesoporous silicon microparticles for oral drug delivery: loading and release of five model drugs. J Control Release 2005;108:362-74
96. Shrestha N, Shahbazi MA, Araujo F, et al. Chitosan-modified porous silicon microparticles for enhanced permeability of insulin across intestinal cell monolayers. Biomaterials 2014;35:7172-9
97. Liu D, Bimbo LM, Makila E, et al. Co-delivery of a hydrophobic small molecule and a hydrophilic peptide by porous silicon nanoparticles. J Control Release 2013;170:268-78
98. Zhang H, Liu D, Shahbazi MA, et al. Fabrication of a multifunctional nano-in-micro drug delivery platform by microfluidic templated encapsulation of porous silicon in polymer matrix. Adv Mater 2014;26:4497-503
99. Bimbo LM, Sarparanta M, Santos HA, et al. Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats. ACS Nano 2010;4:3023-32
100. Li YF, Chen C. Fate and toxicity of metallic and metal-containing nanoparticles for biomedical applications. Small 2011;7:2965-80
101. Hillyer JF, Albrecht RM. Gastrointestinal persorption and tissue distribution of differently sized colloidal gold nanoparticles. J Pharm Sci 2001;90:1927-36
102. Pokharkar V, Dhar S, Bhumkar D, et al. Acute and subacute toxicity studies of chitosan reduced gold nanoparticles: a novel carrier for therapeutic agents. J Biomed Nanotechnol 2009;5:233-9
103. Zhang XD, Wu HY, Wu D, et al. Toxicologic effects of gold nanoparticles in vivo by different administration routes. Int J Nanomedicine 2010;5:771-81
104. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater 2013;12:991-1003
105. Kumari M, Rajak S, Singh SP, et al. Biochemical alterations induced by acute oral doses of iron oxide nanoparticles in wistar rats. Drug Chem Toxicol 2013;36:296-305
106. Singh SP, Rahman MF, Murty US, et al. Comparative study of genotoxicity and tissue distribution of nano and micron sized iron oxide in rats after acute oral treatment. Toxicol Appl Pharmacol 2013;266:56-66
107. Maham A, Tang Z, Wu H, et al. Protein-based nanomedicine platforms for drug delivery. Small 2009;5:1706-21
108. Shapira A, Assaraf Y, Epstein D, et al. Beta-casein nanoparticles as an oral delivery system for chemotherapeutic drugs: impact of drug structure and properties on co-assembly. Pharm Res 2010;27:2175-86
109. Chen L, Subirade M. Chitosan/beta-lactoglobulin core-shell nanoparticles as nutraceutical carriers. Biomaterials 2005;26:6041-53
110. Golla K, Bhaskar C, Ahmed F, et al. A target-specific oral formulation of doxorubicin-protein nanoparticles: efficacy and safety in hepatocellular cancer. J Cancer 2013;4:644-52
111. Jos A, Pichardo S, Puerto M, et al. Cytotoxicity of carboxylic acid functionalized single wall carbon nanotubes on the human intestinal cell line caco-2. Toxicol In Vitro 2009;23:1491-6
112. Cicchetti R, Divizia M, Valentini F, et al. Effects of single-wall carbon nanotubes in human cells of the oral cavity: geno-cytotoxic risk. Toxicol In Vitro 2011;25:1811-19
113. Folkmann JK, Risom L, Jacobsen NR, et al. Oxidatively damaged DNA in rats exposed by oral gavage to c60 fullerenes and single-walled carbon nanotubes. Environ Health Perspect 2009;117:703-8
114. Kolosnjaj-Tabi J, Hartman KB, Boudjemaa S, et al. In vivo behavior of large doses of ultrashort and full-length single-walled carbon nanotubes after oral and intraperitoneal administration to swiss mice. ACS Nano 2010;4:1481-92
115. Naya M, Kobayashi N, Mizuno K, et al. Evaluation of the genotoxic potential of single-wall carbon nanotubes by using a battery of in vitro and in vivo genotoxicity assays. Toxicol Lett 2011;205:S286-6